Scotiabank analyst Sung Ji Nam last night initiated coverage of Twist Bioscience with an Outperform rating and $33 price target. The analyst started coverage on nine companies in the life science tools and diagnostics space with a positive view on the sector. Twist manufactures synthetic DNA, leveraging its proprietary technology platform for various products including synthetic genes, next-generation sequencing sample preparation, and antibody libraries for drug discovery and development, Ji Nam tells investors in a research note. The analyst says the company has a "strong track record and momentum" heading into 2023 and beyond.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TWST:
- Twist Bioscience initiated with an Outperform at Scotiabank
- Azenta downgraded to In Line at Evercore ISI on share loss
- Twist Bioscience upgraded at Evercore ISI with accounting fears eased
- Twist Bioscience upgraded to Outperform from In Line at Evercore ISI
- Twist Bioscience Nosedives on Short Seller Report
